国家老龄化研究所-阿尔茨海默病协会关于阿尔茨海默病神经病理学评估的指南。
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.
机构信息
Department of Neurology, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
出版信息
Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007.
Abstract
A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre-clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP-43 inclusions, and recommend standard approaches for the workup of cases and their clinico-pathologic correlation.
摘要
最近，来自美国和欧洲的一个共识小组召开会议，更新和修订了 1997 年关于老年人群中常见的阿尔茨海默病（AD）和其他脑部疾病的神经病理学评估的共识指南。新指南承认 AD 的临床前阶段，增强了 AD 的评估，包括淀粉样蛋白积累以及神经纤维缠结和神经原纤维缠结，为路易体病、血管性脑损伤、海马硬化和 TDP-43 包涵体的神经病理学评估制定了方案，并建议对病例进行标准检查及其临床病理相关性。
相似文献
1
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.
Alzheimers Dement. 2012 Jan;8(1):1-13. doi: 10.1016/j.jalz.2011.10.007.
2
Revised criteria for diagnosis of Alzheimer's disease: National Institute on Aging-Alzheimer's Association diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):253-6. doi: 10.1016/j.jalz.2011.04.003.
3
Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):257-62. doi: 10.1016/j.jalz.2011.03.004. Epub 2011 Apr 21.
4
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.
Acta Neuropathol. 2012 Jan;123(1):1-11. doi: 10.1007/s00401-011-0910-3. Epub 2011 Nov 20.
5
Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century.
Alzheimers Dement. 2011 May;7(3):335-7. doi: 10.1016/j.jalz.2011.04.002.
6
Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010.
J Neuropathol Exp Neurol. 2012 Apr;71(4):266-73. doi: 10.1097/NEN.0b013e31824b211b.
7
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
8
Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease".
Alzheimers Dement. 2011 May;7(3):333-4. doi: 10.1016/j.jalz.2011.04.001.
9
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
10
Performance of a Condensed Protocol That Reduces Effort and Cost of NIA-AA Guidelines for Neuropathologic Assessment of Alzheimer Disease.
J Neuropathol Exp Neurol. 2017 Jan 1;76(1):39-43. doi: 10.1093/jnen/nlw104.
引用本文的文献
1
Associations between trajectories of plasma biomarkers for Alzheimer's disease, brain structures, and cognitive function: a prospective cohort study in the UK Biobank.
Mol Psychiatry. 2025 Aug 28. doi: 10.1038/s41380-025-03166-y.
2
Recent Advances and Future Directions in Alzheimer's Disease Genetic Research.
Int J Mol Sci. 2025 Aug 13;26(16):7819. doi: 10.3390/ijms26167819.
3
Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.
Mar Drugs. 2025 Jul 30;23(8):310. doi: 10.3390/md23080310.
4
Key questions for the future of amyloid research in dementia: a framework for integrating complex datasets.
Mol Psychiatry. 2025 Aug 22. doi: 10.1038/s41380-025-03156-0.
5
Hippocampal tau distribution in primary age-related tauopathy: The Vantaa 85+ Study.
Alzheimers Dement. 2025 Aug;21(8):e70613. doi: 10.1002/alz.70613.
6
Imaging brain class I histone deacetylase changes in the Lewy body dementias and Parkinson's disease.
Res Sq. 2025 Aug 11:rs.3.rs-6647341. doi: 10.21203/rs.3.rs-6647341/v1.
7
F-FDG PET in detection of primary age-related tauopathy (PART) - Is there a role? Insights from an imaging-pathology correlation study.
Alzheimers Dement. 2025 Aug;21(8):e70568. doi: 10.1002/alz.70568.
8
Pathologic burden goes with the flow: MRI perfusion and pathologic burden in frontotemporal lobar degeneration due to tau.
Imaging Neurosci (Camb). 2024 Mar 22;2. doi: 10.1162/imag_a_00118. eCollection 2024.
9
MIND Diet and Hippocampal Sclerosis Among Community-Based Older Adults.
JAMA Netw Open. 2025 Aug 1;8(8):e2526089. doi: 10.1001/jamanetworkopen.2025.26089.
10
Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles.
Eur J Nucl Med Mol Imaging. 2025 Aug 6. doi: 10.1007/s00259-025-07457-y.
本文引用的文献
1
Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.
J Neuropathol Exp Neurol. 2011 Nov;70(11):960-9. doi: 10.1097/NEN.0b013e318232a379.
2
Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association.
Stroke. 2011 Sep;42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
3
The association between blood pressure and incident Alzheimer disease: a systematic review and meta-analysis.
Epidemiology. 2011 Sep;22(5):646-59. doi: 10.1097/EDE.0b013e31822708b5.
4
Is high homocysteine level a risk factor for cognitive decline in elderly? A systematic review, meta-analysis, and meta-regression.
Am J Geriatr Psychiatry. 2011 Jul;19(7):607-17. doi: 10.1097/JGP.0b013e3181f17eed.
5
Hippocampal sclerosis in advanced age: clinical and pathological features.
Brain. 2011 May;134(Pt 5):1506-18. doi: 10.1093/brain/awr053.
6
Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's disease.
Acta Neuropathol. 2011 Jul;122(1):49-60. doi: 10.1007/s00401-011-0831-1. Epub 2011 May 1.
7
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):263-9. doi: 10.1016/j.jalz.2011.03.005. Epub 2011 Apr 21.
8
The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):270-9. doi: 10.1016/j.jalz.2011.03.008. Epub 2011 Apr 21.
9
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Alzheimers Dement. 2011 May;7(3):280-92. doi: 10.1016/j.jalz.2011.03.003. Epub 2011 Apr 21.
10
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease.
Nat Genet. 2011 May;43(5):436-41. doi: 10.1038/ng.801. Epub 2011 Apr 3.
Zotero 插件